OxProtect is a company (SME) that develops new test procedures and active substances in the field of hemostasis and inflammation, founded in 2014. The research focus of the OxProtect GmbH is to examine blood cells on the activation status or the functional capacity (platelets, monocytes, granulocytes, t-cells), but also endothelial cells and joint cells. The function of the cells as well as the changes or activity can be analysed by flow cytometry, aggregation assays, adhesion assays or ELISA assays.

Not only human cell function testing but also animal cell function testing is established in the OxProtect GmbH, for example for mouse, rat, rabbit, sheep, or many other animal species cells. On these cells OxProtect can examine for example antibody binding, antigen binding, morphology, cell associate formation and cell fragmentation.

OxProtect moreover offers new developed analytical methods in the area of misfolded proteins, which among other things are built within and/or after diseases. These misfolded proteins play a pivotal role in blood coagulation and inflammation.

For protein qualification and quantification with special tools we use techniques like SDS-PAGE, 2D electrophoresis, and Western Blot analysis, for cell analysis approved and new developed immunocytochemistry assays.

1) Lenz-Habijan T, Brodde M, Kehrel BE, Bannewitz C, Gromann K, Bhogal P, Aguilar Perez M, Monstadt H, Henkes H. Comparison of the Thrombogenicity of a Bare and Antithrombogenic Coated Flow Diverter in an In Vitro Flow Model. Cardiovasc Intervent Radiol. 2020 Jan;43(1):140-146.

2) Bertling A, Fender AC, Schüngel L, Rumpf M, Mergemeier K, Geißler G, Sibrowski W, Kelsch R, Waltenberger J, Jakubowski JA, Kehrel BE. Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor.J Thromb Haemost. 2018 Jun;16(6):1089-1098.

3) Boncler M, Kehrel B, Szewczyk R, Stec-Martyna E, Bednarek R, Brodde M, Watala C. Oxidation of C-reactive protein by hypochlorous acid leads to the formation of potent platelet activator.Int J Biol Macromol. 2018 Feb;107(Pt B):2701-2714.

4) Bertling A, Brodde MF, Visser M, Treffon J, Fennen M, Fender AC, Kelsch R, Kehrel BE. Components in Plasma-Derived Factor VIII, But Not in Recombinant Factor VIII Downregulate Anti-Inflammatory Surface Marker CD163 in Human Macrophages through Release of CXCL4 (Platelet Factor 4).Transfus Med Hemother. 2017 Sep;44(5):351-357.

5) Göbel K, Kraft P, Pankratz S, Gross CC, Korsukewitz C, Kwiecien R, Mesters R, Kehrel BE, Wiendl H, Kleinschnitz C, Meuth SG. Prothrombin and factor X are elevated in multiple sclerosis patients. Ann Neurol. 2016 Dec;80(6):946-951.